Published: April 11, 2025
Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.
Read MoreLearn how to use the site
Watch Tutorial
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras fermentum ultrices varius. Vivamus cursus turpis sed finibus ultricies. Nullam id mauris accumsan tellus facilisis eleifend. Vivamus sed lorem sit amet nisi gravida maximus. Suspendisse consequat auctor lacus et laoreet. In hac habitasse platea dictumst. Praesent ultricies elit sagittis felis lobortis, nec aliquam arcu gravida.
